Insilico Medicine Launches AI-powered COVIDomic for COVID-19 Research

Santa Clara, CA – Insilico Medicine, a leader in artificial intelligence for drug discovery and development, announced the launch of a system for COVID-19 basic and clinical research. COVIDomic is a foundational technology that enables scientists to use anonymized patient data to integrate with a variety of existing data sets. Bioinformatics and AI tools can […]

AI and Blockchain Companies Partner to Advance Healthcare Research

Today Insilico Medicine announced a research collaboration with The Bitfury Group, the world’s leading full-service blockchain technology conglomerate, to develop novel solutions for healthcare applications. The companies signed a memorandum of understanding (MOU) to collaborate in the academic and commercial settings to develop AI on Blockchain solutions for the healthcare industry.

Blockchain can secure and streamline our medical systems, while AI has the potential to revitalize data management and machine learning to help identify trends and diseases,” said Valery Vavilov, founder, and CEO of The Bitfury Group. “By partnering with Insilico, we will be able to combine their expertise in deep learning and bioinformatics with our Blockchain proficiency and real-time solutions to create bespoke and innovative new products for the healthcare sector.”

Insilico Applies Deep Learning to Drug Discovery

“The world of artificial intelligence is rapidly evolving and affecting every aspect of our daily life. And soon this progress will be felt in the pharmaceutical industry. We set up the Pharma.AI division to help pharmaceutical companies significantly accelerate their R&D and increase the number of approved drugs, but in the process we came up with over 800 strong hypotheses in oncology, cardiovascular, metabolic and CNS space and started basic validation. We are cautious about making strong statements, but if this approach works, it will uberize the pharmaceutical industry and generate unprecedented number of QALY,” said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.